4381

News

bio Daniel Tang 2020 200x245 - Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.

Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.

Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.

Daniel has over 23 years’ experience in biotech/pharmaceutical and the CRO industry. Prior to Frontage, he was COO of Phanes Therapeutics. He also held various leadership positions with increasing scientific and managerial responsibilities, including CEO of United-Power Pharmatech (UPP), a biologics bioassay CRO in specializing in biologics/biosimilars PK, ADA, and Nab assays, GM at ICON APAC, VP of bioanalysis/DMPK at Frontage (China).

Dr. Tang has authored or co-authored more than 50 research papers/conference white papers and has chaired various international conferences in regulated bioanalysis. He was also one of the leading authors for the AAPS white paper on Incurred Sample Re-analysis. He was a steering committee member of Global Bioanalytical Consortium, representing APAC. He also was instrumental in establishing China Bioanalysis Forum (CBF), the first bioanalysis focused group in China. Dr. Tang was the chair of Special Interest Group (SIG) of Analytical Sciences and Pharmaceutical Quality (ASPQ) in International Pharmaceutical Federation (FIP).

Dr. Tang holds a PhD degree in Analytical Chemistry from the George Washington University and an MBA degree from University of Michigan.